On April 12, Friends of Cancer Research held a briefing on Capitol Hill on the topic of Breakthrough Therapy Designation: Successes, Lessons Learned and Future Strategies. Through the breakthrough therapy program, which followed the passage of the Food and Drug Administration Safety and Innovation Act (FDASIA) in 2012, a new drug may be designated as […]
Research, Science and Treatments
The Meso Foundation recently hosted a Meet the Mesothelioma Experts session with Dr. Raphael Bueno, the chief of thoracic surgery at Brigham and Women’s Hospital in Boston, MA. He was interviewed by Mary Hesdorffer, the Meso Foundation’s executive director and nurse practitioner, and discussed his work and the future of his mesothelioma program.
When asked about […]
In our previous blog post opening this year’s Global Asbestos Awareness Week, we mentioned that prevention of mesothelioma can take several different shapes. Avoiding exposures to asbestos is one such method. However, while theoretically valid, in reality this method falls short in accomplishing this goal because asbestos is showing no signs of going away. It […]
The Meso Foundation released a statement from its executive director, Mary Hesdorffer, APRN, about AstraZeneca’s tremelimumab trial for mesothelioma.
In an AstraZeneca press release issued yesterday, the company states that “DETERMINE, the Phase IIb clinical trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint […]
In the first of a special two-part series of Meet the Mesothelioma Experts, we interview our 2015 mesothelioma research grant recipients. In this session, we interview grant recipients Dr. Andrea McClatchey of the Massachusetts General Hospital in Boston, Dr. Sean Carlin of Memorial Sloan Kettering Cancer Center in New York, and Dr. Jill Ohar of […]